MINNEAPOLIS -- The novel dual-function cardiac contractility modulation-defibrillator (CCM-D) for heart failure with reduced ejection fraction (HFrEF) had favorable early results in the Integra-D ...

Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter ...

Gaithersburg, MD - Medtronic Inc's (Minneapolis, MN) InSync® cardiac resynchronization device to treat severe heart failure (HF) has won a unanimous recommendation for approval by the FDA's ...

The major trials that established cardiac resynchronization therapy (CRT) as a treatment for heart failure (HF) with reduced ejection fraction (HFrEF) tended not to include patients who already had ...

St. Paul, MN, March 9, 2004 -- St. Jude Medical, Inc. (NYSE: STJ) announced today that data from its RHYTHM (Resynchronization HemodYnamic Treatment for Heart Failure Management) ICD clinical trial ...

SUNNYVALE, Calif.--(BUSINESS WIRE)--EBR Systems, Inc., developer of the world’s only wireless cardiac pacing system for heart failure, today announced the publication of a case report demonstrating ...

Results from the Cardiac Resynchronization—Heart Failure (CARE-HF) study support the use of implantable cardiac-resynchronization devices in patients with heart failure due to left-ventricular ...

Drs Venkat D Nagarajan, consultant, Cardiac Electrophysiologist and Dr Jamshed Dalal, director of of Cardiac Sciences at the Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute, Mumbai ...

A widely anticipated heart disease study released Tuesday could boost the use of an advanced type of heart defibrillator made by companies with strong roots in Minnesota. The 1,820-patient study -- ...

The U.S. cardiac resynchronization therapy market was valued at $965.6 million in 2019, and is projected to reach $983.3 million by 2027, registering a CAGR of 4.9% from 2020 to 2027. Surge in ...